4.70 USD
▲-0.09+1.95%
2026-08-03
市值
$376.13M
市盈率
—
EPS
-2.12
股息率
—
52 周区间
2.78 – 6.45
成交量
406.39K
Beta
0.32
目标价
8.67
52W 低 2.7852W 高 6.45
价格走势
公司简介
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of ...